avapro has been researched along with Hyperphosphatemia in 1 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Short treatment duration, lower pretreatment proteinuria than expected." | 2.90 | Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. ( Aparicio, C; Bellasi, A; Cannata, A; Cozzolino, M; Ferrari, S; Kohan, DE; Lecchi, V; Mallamaci, F; Mazzaferro, S; Peraro, F; Perna, A; Perticucci, E; Remuzzi, G; Rotondi, S; Ruggenenti, P; Ruggiero, B; Tartaglione, L; Trillini, M; Tripepi, R; Villa, D; Zoccali, C, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruggiero, B | 1 |
| Trillini, M | 1 |
| Tartaglione, L | 1 |
| Rotondi, S | 1 |
| Perticucci, E | 1 |
| Tripepi, R | 1 |
| Aparicio, C | 1 |
| Lecchi, V | 1 |
| Perna, A | 1 |
| Peraro, F | 1 |
| Villa, D | 1 |
| Ferrari, S | 1 |
| Cannata, A | 1 |
| Mazzaferro, S | 1 |
| Mallamaci, F | 1 |
| Zoccali, C | 1 |
| Bellasi, A | 1 |
| Cozzolino, M | 1 |
| Remuzzi, G | 1 |
| Ruggenenti, P | 1 |
| Kohan, DE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Multicenter, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess the Renal and Humoral Effects of Sevelamer Carbonate in Patients With Chronic Kidney Disease and Residual Proteinuria Despite Best Available Treatment[NCT01968759] | Phase 2 | 53 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for avapro and Hyperphosphatemia
| Article | Year |
|---|---|
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chelating Agents; Cross-Over Studies; Drug Monitoring; Dru | 2019 |